Optimization of naked DNA delivery for interferon subtype immunotherapy in cytomegalovirus infection

Emmalene J. Bartlett; Vanessa S. Cull; Eva N. Mowe; Josephine P. Mansfield; Cassandra M. James

doi:10.1251/bpo45

Optimization of naked DNA delivery for interferon subtype immunotherapy in cytomegalovirus infection

Emmalene J. Bartlett, Vanessa S. Cull, Eva N. Mowe, Josephine P. Mansfield, Cassandra M. James

Research output: Contribution to journal › Article › peer-review

6 Citations (Scopus)

Abstract

Type I interferon (IFN) gene therapy modulates the immune response leading to inflammatory heart disease following cytomegalovirus (CMV) infection in a murine model of postviral myocarditis. Efficacy of different immunisation protocols for the IFN constructs was influenced by the dose of DNA, subtype choice, combination use, pre-medication, and timing of DNA administration. Optimal efficacy was found with bupivacaine treatment prior to DNA inoculation of 200μg IFN DNA 14 days prior to virus challenge. Maximal antiviral and antimyocarditic effects were achieved with this vaccination schedule. Furthermore, inoculation of synergistic IFN subtypes demonstrated enhanced efficacy when delivered either alone or with CMV gB DNA vaccination in the CMV model. Thus naked DNA delivery of IFN provides an avenue of immunotherapy for regulating herpesvirus-induced diseases.

Original language	English
Pages (from-to)	43-52
Number of pages	10
Journal	Biological Procedures Online
Volume	5
Issue number	1
DOIs	https://doi.org/10.1251/bpo45
Publication status	Published - 1 Dec 2003
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1251/bpo45

Cite this

@article{dc3ba17d43c746d1863a4066eb6f6a08,

title = "Optimization of naked DNA delivery for interferon subtype immunotherapy in cytomegalovirus infection",

abstract = "Type I interferon (IFN) gene therapy modulates the immune response leading to inflammatory heart disease following cytomegalovirus (CMV) infection in a murine model of postviral myocarditis. Efficacy of different immunisation protocols for the IFN constructs was influenced by the dose of DNA, subtype choice, combination use, pre-medication, and timing of DNA administration. Optimal efficacy was found with bupivacaine treatment prior to DNA inoculation of 200μg IFN DNA 14 days prior to virus challenge. Maximal antiviral and antimyocarditic effects were achieved with this vaccination schedule. Furthermore, inoculation of synergistic IFN subtypes demonstrated enhanced efficacy when delivered either alone or with CMV gB DNA vaccination in the CMV model. Thus naked DNA delivery of IFN provides an avenue of immunotherapy for regulating herpesvirus-induced diseases.",

keywords = "Cytomegalovirus, DNA, Gene therapy, Interferons",

author = "Bartlett, \{Emmalene J.\} and Cull, \{Vanessa S.\} and Mowe, \{Eva N.\} and Mansfield, \{Josephine P.\} and James, \{Cassandra M.\}",

year = "2003",

month = dec,

day = "1",

doi = "10.1251/bpo45",

language = "English",

volume = "5",

pages = "43--52",

journal = "Biological Procedures Online",

issn = "1480-9222",

publisher = "BioMed Central",

number = "1",

}

TY - JOUR

T1 - Optimization of naked DNA delivery for interferon subtype immunotherapy in cytomegalovirus infection

AU - Bartlett, Emmalene J.

AU - Cull, Vanessa S.

AU - Mowe, Eva N.

AU - Mansfield, Josephine P.

AU - James, Cassandra M.

PY - 2003/12/1

Y1 - 2003/12/1

N2 - Type I interferon (IFN) gene therapy modulates the immune response leading to inflammatory heart disease following cytomegalovirus (CMV) infection in a murine model of postviral myocarditis. Efficacy of different immunisation protocols for the IFN constructs was influenced by the dose of DNA, subtype choice, combination use, pre-medication, and timing of DNA administration. Optimal efficacy was found with bupivacaine treatment prior to DNA inoculation of 200μg IFN DNA 14 days prior to virus challenge. Maximal antiviral and antimyocarditic effects were achieved with this vaccination schedule. Furthermore, inoculation of synergistic IFN subtypes demonstrated enhanced efficacy when delivered either alone or with CMV gB DNA vaccination in the CMV model. Thus naked DNA delivery of IFN provides an avenue of immunotherapy for regulating herpesvirus-induced diseases.

AB - Type I interferon (IFN) gene therapy modulates the immune response leading to inflammatory heart disease following cytomegalovirus (CMV) infection in a murine model of postviral myocarditis. Efficacy of different immunisation protocols for the IFN constructs was influenced by the dose of DNA, subtype choice, combination use, pre-medication, and timing of DNA administration. Optimal efficacy was found with bupivacaine treatment prior to DNA inoculation of 200μg IFN DNA 14 days prior to virus challenge. Maximal antiviral and antimyocarditic effects were achieved with this vaccination schedule. Furthermore, inoculation of synergistic IFN subtypes demonstrated enhanced efficacy when delivered either alone or with CMV gB DNA vaccination in the CMV model. Thus naked DNA delivery of IFN provides an avenue of immunotherapy for regulating herpesvirus-induced diseases.

KW - Cytomegalovirus

KW - DNA

KW - Gene therapy

KW - Interferons

UR - https://www.scopus.com/pages/publications/0042684700

U2 - 10.1251/bpo45

DO - 10.1251/bpo45

M3 - Article

AN - SCOPUS:0042684700

SN - 1480-9222

VL - 5

SP - 43

EP - 52

JO - Biological Procedures Online

JF - Biological Procedures Online

IS - 1

ER -

Optimization of naked DNA delivery for interferon subtype immunotherapy in cytomegalovirus infection

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this